Balaji Amines Posts Strong Q4 Profit Jump, Declares Dividend Amidst Rising Debt

Balaji Amines Ltd. reported its full-year results, with consolidated revenue at ₹1,45,378.74 lakhs for FY26, and net profit at ₹16,915.68 lakhs. The company also announced a strong Q4 FY26 performance, where net profit surged 60.16% year-on-year to ₹6,477.05 lakhs.

Reader Takeaway: Annual profit grew 6.66%; significant debt rise is a key concern.

What just happened (today’s filing)

Balaji Amines Ltd. announced its financial results for the quarter and year ended March 31, 2026.

The company's consolidated net profit for Q4 FY26 dramatically increased by 60.16% to ₹6,477.05 lakhs compared to ₹4,043.99 lakhs in the same period last year.

Total revenue for the quarter rose by a healthy 11.58% year-on-year to ₹40,252.48 lakhs.

For the full fiscal year FY26, consolidated revenue grew by 1.64% to ₹1,45,378.74 lakhs, while net profit saw a more modest increase of 6.66% to ₹16,915.68 lakhs.

Reflecting confidence, the board recommended a final dividend of ₹11 per equity share.

Auditors issued an unmodified opinion, signaling clean financial reporting.

Why this matters

The strong Q4 performance indicates robust demand for Balaji Amines' products, potentially from sectors like pharmaceuticals and agrochemicals.

The dividend payout signals management's commitment to shareholder returns.

However, the substantial increase in debt requires investor attention.

The backstory (grounded)

Balaji Amines has been strategically expanding its manufacturing capacities, including through its subsidiary Balaji Specialty Chemicals.

These expansion drives typically involve significant capital expenditure, often financed through a mix of internal accruals and external borrowings.

What changes now

Shareholders will receive a ₹11 per equity share dividend for FY26.

Increased debt levels may lead to higher interest expenses in future quarters.

The company's growth trajectory might be supported by recent capacity additions, if debt was used for capex.

Investors will closely monitor the utilization of new debt and its impact on profitability and cash flows.

Risks to watch

Current borrowings have surged from ₹909.09 lakhs to ₹6,807.70 lakhs.

Non-current borrowings have also risen sharply from ₹151.52 lakhs to ₹6,483.35 lakhs.

Higher interest costs from increased debt could pressure profit margins.

Peer comparison

Alkyl Amines Chemicals Ltd., a key competitor, also operates in the aliphatic amines segment and has a similar market focus.

Aether Industries and Neogen Chemicals are other prominent specialty chemical players, focusing on custom synthesis and niche products respectively.

Context metrics (time-bound)

Consolidated annual revenue stood at ₹1,45,378.74 lakhs for FY26, a 1.64% increase from ₹1,43,028.76 lakhs in FY25.

Consolidated net profit for FY26 was ₹16,915.68 lakhs, up 6.66% year-on-year.

Current borrowings increased to ₹6,807.70 lakhs as of March 31, 2026, from ₹909.09 lakhs a year prior.

What to track next

Management commentary on the reasons for the significant debt increase and repayment plans.

Utilization of borrowed funds and its contribution to future revenue streams.

The company's strategy to manage higher interest outgo.

Future capacity utilization and demand outlook for its key product segments.

Commentary on profit margins in upcoming quarters given increased finance costs.